Humacyte, Inc.

NASDAQ:HUMA

Biotechnology

Healthcare
$0.50 -3.35%

-$0.03 today

Market cap
$139.18M
Beta
2.46
P/E (TTM)
-1.9
EPS (TTM)
-$0.49
52W Low $0.55High $2.84

Volume 4.34M

Average 8.14M

HUMA Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Humacyte, Inc.NASDAQ: HUMA

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to -311.7%

Gross margin was -311.7% in Q1 FY2026, down 28.9 pp from a year earlier. On a trailing-twelve-month basis it was -748.5%, down 729.4 pp year over year. Over 3 fiscal years it narrowed by 309.0 pp.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-311.7%+1915.9 pp QoQ
Last fiscal yearDec 2025
-736.5%— YoY
LTMMar 2026
-748.5%-729.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-28.9 pp——
1 year———
3 years-309.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
-736.5%
Year-over-year change
—

Gross Margin vs competitors

How HUMA compares with its peers on the latest reported figures

  • HUMA's LTM Mar 2026 gross margin of -748.5% is the lowest of the 6 companies compared; the peer median is 22.3%.
  • Its year-over-year change of -729.4 pp is the lowest of 6, against a peer median of -8.8 pp.
  • Over three fiscal years its change of -309.0 pp compares with a peer median of -0.5 pp.
HUMA Competitors Peer median
Gross Margin for HUMA and competitors
Company Period LTM level YoY 3-year change
VNDAVanda Pharmaceuticals Inc.LTM Mar 202692.5% -1.0 pp+3.5 pp
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202691.2% -8.8 pp-4.5 pp
FHTXFoghorn Therapeutics Inc.LTM Mar 202622.3% -77.7 pp-10.8 pp
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-86.7% +2.3 pp+136.3 pp
TRDAEntrada Therapeutics, Inc.LTM Mar 2026-598.0% -698.0 pp—
HUMAHumacyte, Inc.LTM Mar 2026-748.5% -729.4 pp-309.0 pp
ACHVAchieve Life Sciences, Inc.FY2025— ——
AVIRAtea Pharmaceuticals, Inc.FY2025— ——
SGMTSagimet Biosciences Inc.FY2025— ——
NAUTNautilus Biotechnology, Inc.FY2025— ——
IMRXImmuneering CorporationFY2025— ——
Peer median (excluding HUMA) 22.3%-8.8 pp-0.5 pp

Competitors are the stored peer set for HUMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.26M1.57M002.04M
Cost of Revenue61.34M8.26M76.55M7.19M17.05M
Gross Profit(60.08M)(6.69M)(76.55M)(7.19M)(15.01M)
Gross Margin-4756.8%-427.5%——-736.5%
Research & Development61.34M63.26M76.55M88.6M69.3M
Selling, General & Admin21.13M22.88M20.39M25.8M31.17M
Operating Expenses21.13M77.89M23.5M107.21M92.43M
Depreciation & Amortization8.24M8.21M7.72M7.19M7.35M
EBITDA(13.89M)2.45M(96.46M)(132.23M)(22.24M)
EBITDA Margin-1099.6%156.2%——-1091.2%
Operating Income(81.21M)(84.58M)(100.05M)(114.4M)(107.44M)
Operating Margin-6429.8%-5404.3%——-5271.7%
Interest Income16K2.63M5.47M4.1M2.59M
Interest Expense4.35M6.2M6.6M9.28M11.25M
Other Income / Expenses54.73M72.61M(10.73M)(34.3M)66.6M
Income Before Tax(26.48M)(11.97M)(110.78M)(148.7M)(40.83M)
Pre-Tax Margin-2096.4%-764.5%——-2003.6%
Income Tax Expense00000
Net Income(26.48M)(11.97M)(110.78M)(148.7M)(40.83M)
Net Margin-2096.4%-764.5%——-2003.6%
EPS (Basic)(0.66)(0.12)(1.07)(1.26)(0.26)
EPS (Diluted)(0.66)(0.12)(1.07)(1.26)(0.26)
Weighted Avg Shares39.97M103.05M103.42M118.48M158.16M
Weighted Avg Shares (Diluted)39.97M103.05M103.42M118.48M158.16M

Humacyte, Inc.

NASDAQ:HUMA

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.